Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Chico
Isagani M
IM
Division of Oncologic Drug Products, Food and Drug Administration, Rockville, MD, USA.
Pazdur
Richard
R
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002166:Camptothecin / Q000009:adverse effects* / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000401:mortality*; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing; D016019:Survival Analysis; D014481:United States; D014486:United States Food and Drug Administration
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin